ArticlePathology oncology research : POR2009
Expression of tight junction protein claudin-4 in basal-like breast carcinomas.
Article in Pathology oncology research : POR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 63 citations in OpenAlex.
- CK8/18 and Claudin Profile of Female Breast Cancers from Botswana.Breast cancer : basic and clinical research · 2026Article
- Invasive micropapillary carcinoma of the breast and invasive breast carcinoma of no special type: a comparison of claudin proteins' expression and its impact on survival.Pathology oncology research : POR · 2024Article
- Expression of Claudin-9 (CLDN9) in Breast Cancer, the Clinical Significance in Connection with Its Subcoat Anchorage Proteins ZO-1 and ZO-3 and Impact on Drug Resistance.Biomedicines · 2023Article
- Claudins as biomarkers of differential diagnosis and prognosis of tumors.Journal of cancer research and clinical oncology · 2021Review
- Comprehensive analysis of expression and prognostic value of the claudin family in human breast cancer.Aging · 2021Article
- Article
- E7 oncoprotein from human papillomavirus 16 alters claudins expression and the sealing of epithelial tight junctions.International journal of oncology · 2020Article
- All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4.Pathology oncology research : POR · 2020Article
- Review
- Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer.Experimental and therapeutic medicine · 2019Article
- Functionalization of gold-nanoparticles by the Clostridium perfringens enterotoxin C-terminus for tumor cell ablation using the gold nanoparticle-mediated laser perforation technique.Scientific reports · 2018Article
- Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.Molecular and clinical oncology · 2018Article
- High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.BMC cancer · 2018Article
- The role of claudins in cancer metastasis.Oncogene · 2017Review
- Claudins in cancer: bench to bedside.Pflugers Archiv : European journal of physiology · 2017Review
- Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.Breast cancer research and treatment · 2016Article
- Mechanisms involved in breast cancer liver metastasis.Journal of translational medicine · 2015Review
- Article
- Emerging roles of claudins in human cancer.International journal of molecular sciences · 2013Review
- Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Claudins (CLDN) are tight junction proteins which contribute to the paracellular transport and ionic permeability of various epithelia. In recent years they came into focus for their suggested role in carcinogenesis and possible role in cancer therapy. According to our previous studies, in breast tissue CLDN4 is also related to the level of cellular differentiation. Thirty-eight estrogen (ER) and progesterone receptor (PgR) negative, HER2/neu negative, but cytokeratin 5/6 positive basal-like-mainly grade 3-breast carcinomas were compared with twenty-one grade 1, twenty-five grade 2 and twenty grade 3 non-basal-like invasive breast carcinomas, in respect to their CLDN4 expression. The immunohistochemical reactions were evaluated both semiquantitatively and by morphometrical analysis. Statistically significant difference (p = 0.001) was observable regarding CLDN4 expression in the basal-like group as compared to grade 1 and 2 cancers. Further, CLDN4 expression was significantly higher (p = 0.017) in the basal-like compared with the non-basal-like grade 3 carcinomas. Our results suggest that basal-like carcinomas are a subset of breast cancer with high level of CLDN4 protein expression. The finding is in accordance with our former observation that CLDN4 is indeed related to cellular differentiation. This observation may be seen as a further proof that basal-like carcinomas represent a separable group amongst grade 3 breast carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.